Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 4
Submit an article Journal homepage
182
Views
6
CrossRef citations to date
0
Altmetric
Review

A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis

Sergio Iannazzo IMS RWE Solutions & HEOR, Milan, Italy. [email protected]; IMS RWE Solutions & HEOR, Milan, Italy. [email protected]
,
Maria De Francesco IMS RWE Solutions & HEOR, Milan, Italy; IMS RWE Solutions & HEOR, Milan, Italy
,
David Gomez-Ulloa IMS RWE Solutions & HEOR, Barcelona, Spain; IMS RWE Solutions & HEOR, Barcelona, Spain
&
Maurizio Benucci Rheumatology Unit, Hospital S Giovanni di Dio, Florence Italy; Rheumatology Unit, Hospital S Giovanni di Dio, Florence Italy
Pages 455-468 | Published online: 09 Jan 2014

References

  • McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205–2219 (2011).
  • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376(9746), 1094–1108 (2010).
  • Temprano K. Rheumatoid Arthritis. Medscape Reference, NY, USA (2012).
  • Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin. Rheumatol. 30(Suppl. 1), S3–S8 (2011).
  • Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology 50(6), 1083–1090 (2011).
  • Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur. J. Health Econ. 8(Suppl. 2), 95–106 (2008).
  • Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J. Manag. Care Pharm. 12(7), 555–569 (2006).
  • NICE TA 130. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE Technology Appraisal Guidance 130 (2007).
  • CADTH, 2010a. Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2010).
  • CADTH, 2010b. Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. CADTH Therapeutic Review Panel. Final Recommendations. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2010).
  • PBAC, 2005. ETANERCEPT, Powder for Injection, 25 mg, ENBREL®. Public Summary Document. PBAC, November (2005).
  • PBAC, 2008. Etanercept, injection set containing 4 vials powder for injection 25 mg and 50 mg and 4 pre-filled syringes solvent 1 mL, and injection 50 mg in 1 mL single use pre-filled syringes, 4, Enbrel®. Public Summary Document. PBAC, July (2008).
  • CADTH, 2006. Coyle D, Judd M, Blumenauer B et al. Infliximab and Etanercept in Patients with Rheumatoid Arthritis: ASystematic Review and Economic Evaluation [Technology report no 64]. Canadian Coordinating Office for Health Technology Assessment, Ottawa (2006).
  • CADTH, 2007a. Suarez-Almazor M, Ortiz Z, Lopez-Olivo M et al. Infliximab and Etanercept in Rheumatoid Arthritis: Systematic Review of Long-Term Clinical Effectiveness, Safety, and Cost-Effectiveness [Technology Report no 85]. Canadian Agency for Drugs and Technologies in Health, Ottawa (2007).
  • CADTH, 2007b. Suarez-Almazor ME, Ortiz Z, Lopez-Olivo M et al. Long-Term Clinical and Cost-Effectiveness of Infliximab and Etanercept for Rheumatoid Arthritis [Technology Overview no 29]. Canadian Agency for Drugs and Technologies in Health, Ottawa (2007).
  • SMC, 2010. Certolizumab pegol, 200 mg/ml solution for injection (prefilled syringe) (Cimzia®). No. (590/09). SMC, September (2010).
  • SMC, 2012. Tocilizumab, 20 mg/mL, concentrate for solution for infusion (RoActemra®). No. (774/12). SMC, March (2012).
  • NICE TA 186. Certolizumab pegol for the treatment of rheumatoid arthritis. NICE Technology Appraisal Guidance 186 (2010).
  • SMC, 2009. Tocilizumab, 20mg/ml concentrate for solution for injection (RoActemra®). No. (593/09). SMC, December (2009).
  • NICE TA 247. Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198. NICE Technology Appraisal Guidance 247 (2012).
  • PBAC, 2009. PBAC Review of bDMARDs for the treatment of severe active rheumatoid athritis. Abatacept (Orencia®), anakinra (Kineret®), adalimumab (Humira®), etanercept (Enbrel®), infliximab (Remicade®), rituximab (Mabthera®). Public Summary Document. PBAC, December (2009).
  • CADTH, 2010c. ABATACEPT RESUBMISSION (Orencia – Bristol-Myers Squibb) Indication: Rheumatoid Arthritis. Common Drug Review. CADTH, June (2010).
  • SMC, 2011b. Golimumab 50 mg solution for injections prefilled pen (auto-injector) or prefilled syringe (Simponi®). No. (733/11). SMC, October 2011b.
  • NICE TA 234. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs. NICE Technology Appraisal Guidance 234 (2011).
  • SMC, 2011a. Abatacept 250 mg powder for concentrate for solution for infusion (Orencia®). No. (719/11). SMC, August 2011.
  • NICE TA 225. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs. NICE Technology Appraisal Guidance 225 (2011).
  • NICE TA 195. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. NICE Technology Appraisal Guidance 195 (2010).
  • PBAC, 2007. Abatacept, powder for I.V. infusion, 250 mg, Orencia®. Public Summary Document. PBAC, November 2007.
  • Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy 108(2–3), 167–177 (2012).
  • Kanavos P, Nicod E, van den Aardweg S et al. The impact of health technology assessments: an international comparison. Euro Observer 12(4), 1–7 (2010).
  • Clement FM, Harris A, Li JJ et al. Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions. A Comparison of Britain, Australia, and Canada. J. Am. Med. Assoc. 302(13), 1437–1443 (2009).
  • Ackermann J, Urbinati D, Strandberg-larsen M et al. PR1 key market access drivers for a successful health technology appraisal outcome – the case of rheumatoid arthritis. Value Health 14(7), A236 (2011).
  • Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care. The role of health technology assessment in the European Union. World Health Organization, on behalf of the European Observatory on Health Systems and Policies (2008).
  • Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69(6), 995–1003 (2010).
  • Corbacho B, Pinto-Prades JL. Health economic decision-making: a comparison between UK and Spain. Br. Med. Bull. 103(1), 1–16 (2012).
  • Sculpher MJ, Drummond MF, Buxton MJ. The iterative use of economic evaluation as part of the process of health technology assessment. J. Health Services. Res. Policy 2, 26–30 (1997).
  • Velasco-Garrido M; Busse R. Health technology assessment. an introduction to objectives, role of evidence, and structure in Europe. WHO, European Observatory on Health Systems and Policies (2005).
  • Pomedli SR. HTA and access to cancer medicines. Euro Observer 12(4), 7–9 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.